Chloe Arrowsmith Jensen

Executive Assistant to Chief Executive Officer at NMD Pharma

Chloe Arrowsmith Jensen has a diverse work experience spanning several industries. Starting in 2007, they worked as a Business Manager at DWA Housing & Management Consultants, where they handled business and risk management, served as the lead contact for the Dorset business, and oversaw project management and strategic business planning. Chloe then moved on to PHSO in 2009, where they held the position of Manager in the Service Delivery Team.

In 2010, Chloe joined CNHC as a Business Manager before transitioning to Stark Investments (UK) LLP later that year. At Stark Investments, they served as a Business & Strategic Development Associate/Researcher until 2012. During this time, Chloe also worked as an Associate Consultant/Researcher at Family Offices.

From 2012 to 2019, Chloe worked at Caxton Associates, initially as a Research/Administration employee and then as a Vice President in Investor Relations. Chloe was responsible for engaging with EMEA & Asia clients and eventually went on maternity leave.

In 2019, Chloe joined British Patient Capital as part of the newly-established Institutional Relations function. Chloe played a key role in managing the function for the £2.5bn Venture Capital Fund of Funds, focusing on areas such as ESG, D&I, and project management. The fund was launched in 2018 as a commercial subsidiary of the UK's government-owned development bank, British Business Bank.

Most recently, Chloe joined NMD Pharma A/S in 2023 as an Executive Assistant to the Chief Executive Officer.

Chloe Arrowsmith Jensen has an extensive education history that spans various fields and institutions. In 2003, they attended the University of Surrey, where they pursued a Bachelor of Arts (Hons) degree in German & Business Culture in Europe. Chloe completed this program in 2007.

In 2011, Chloe obtained the Investment Management Certificate from the CFA Institute at Level 4. The following year, in 2012, they enrolled in the CAIA Association and achieved the CAIA Level I certification in Chartered Alternative Investment Analyst.

Continuing their studies in the field, Chloe completed the CAIA Level II program with the CAIA Association in 2013. During the same year, they also obtained the National Commodity Futures Exam from FINRA, specializing in Series 3.

In 2014, Chloe participated in the Financial Markets program at The Chartered Institute for Securities & Investment (The CISI).

Looking ahead, in 2022, Chloe intends to pursue further education through Danskuddannelse 3, where they will undertake Module 1. The field of study for this certification is not specified.


Previous companies

British Patient Capital logo


View in org chart


  • Executive Assistant to Chief Executive Officer

    January, 2023 - present

View in org chart